CORT
Corcept Therapeutics Incorporated
Price Chart
Latest Quote
$90.52
+0.80 (+0.89%)
Current Price
| Previous Close | $89.72 |
| Open | $88.50 |
| Day High | $91.45 |
| Day Low | $87.22 |
| Volume | 1,859,520 |
Stock Information
| Shares Outstanding | 107.35M |
| Total Debt | $9.64M |
| Cash Equivalents | $338.18M |
| Revenue | $769.10M |
| Net Income | $46.68M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $9.72B |
| P/E Ratio | 258.63 |
| EPS (TTM) | $0.35 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $9.30B |
| Sales | $769.10M |
| Income | $46.68M |
| Book/sh | $5.94 |
| Cash/sh | $3.15 |
| Employees | 730 |
Financial Ratios
| Quick Ratio | 2.53 |
| Current Ratio | 2.86 |
| Debt/Eq | 1.51 |
Returns & Margins
| ROA | -0.62% |
| ROE | 7.17% |
| Gross Margin | 98.25% |
| Operating Margin | -30.08% |
| Profit Margin | 6.16% |
Ownership
| Insider Ownership | 11.54% |
| Institutional Ownership | 75.54% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 28.23 |
| PEG | 0.81 |
| P/S | 12.63 |
| P/B | 15.23 |
Analyst Data
| Recommendation | buy |
| Target Price | $97.50 |
Technical Indicators
| SMA20 | $87.83 |
| SMA50 | $74.98 |
| SMA200 | $61.12 |
| RSI | 56.73 |
| ATR | 3.9073 |
| Shares Float | 89.94M |
| Short Float | 10.39% |
| Short Ratio | 8.57 |
| Volatility | 0.46 |
| Rel Volume | 1.65 |
Performance History
| Week | -1.48% |
| Month | +8.14% |
| Quarter | +105.91% |
| 6 Months | +144.38% |
| YTD | +136.96% |
| Year | +24.26% |
| 3 Years | +298.59% |
| 5 Years | +310.71% |
| 10 Years | +1439.46% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $90.52 | 1,859,520 |
| 2026-07-16 | $89.72 | 878,100 |
| 2026-07-15 | $89.57 | 1,019,900 |
| 2026-07-14 | $90.47 | 1,159,600 |
| 2026-07-13 | $85.90 | 1,325,200 |
| 2026-07-10 | $91.88 | 1,128,500 |
| 2026-07-09 | $93.25 | 1,189,300 |
| 2026-07-08 | $92.94 | 1,037,100 |
| 2026-07-07 | $94.04 | 1,142,000 |
| 2026-07-06 | $91.61 | 1,171,700 |
| 2026-07-02 | $90.21 | 771,900 |
| 2026-07-01 | $88.48 | 1,046,500 |
| 2026-06-30 | $86.95 | 738,700 |
| 2026-06-29 | $87.89 | 864,900 |
| 2026-06-26 | $87.32 | 1,590,800 |
| 2026-06-25 | $84.75 | 1,103,000 |
| 2026-06-24 | $81.56 | 754,000 |
| 2026-06-23 | $79.85 | 947,300 |
| 2026-06-22 | $79.71 | 882,700 |
| 2026-06-18 | $79.91 | 1,875,400 |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
đ° Latest News
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook
Motley Fool âĸ 2026-07-12T19:26:35Z
Why Crinetics Stock Soared 99% This Week
24/7 Wall St. âĸ 2026-07-09T17:29:39Z
3 Cash-Heavy Stocks with Questionable Fundamentals
StockStory âĸ 2026-07-07T08:26:43Z
3 High-Flying Stocks We Steer Clear Of
StockStory âĸ 2026-06-30T12:59:01Z
3 Unpopular Stocks We Steer Clear Of
StockStory âĸ 2026-06-23T08:00:46Z
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
Zacks âĸ 2026-06-18T13:57:00Z
June 2026's Leading Growth Stocks With Strong Insider Ownership
Simply Wall St. âĸ 2026-06-15T17:36:45Z
Esquire Financial Holdings And 2 Insider Picks For Growth Potential
Simply Wall St. âĸ 2026-06-15T11:36:44Z
Spotlight On June 2026's Insider-Favored Growth Stocks
Simply Wall St. âĸ 2026-06-12T17:35:55Z
3 Growth Companies Insiders Are Betting On
Simply Wall St. âĸ 2026-06-12T11:35:44Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $12,977,000 | $10,882,000 | $6,481,000 | $5,385,000 |
| Cost Of Revenue | $12,977,000 | $10,882,000 | $6,481,000 | $5,385,000 |
| Total Revenue | $761,407,000 | $675,040,000 | $482,375,000 | $401,858,000 |
| Operating Revenue | $761,407,000 | $675,040,000 | $482,375,000 | $401,858,000 |
| Expenses | ||||
| Total Expenses | $716,610,000 | $538,089,000 | $375,093,000 | $289,224,000 |
| Net Non Operating Interest Income Expense | $21,666,000 | $24,542,000 | $17,275,000 | $3,557,000 |
| Operating Expense | $703,633,000 | $527,207,000 | $368,612,000 | $283,839,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $99,652,000 | $141,209,000 | $106,140,000 | $101,418,000 |
| Net Interest Income | $21,666,000 | $24,542,000 | $17,275,000 | $3,557,000 |
| Interest Income | $21,666,000 | $24,542,000 | $17,275,000 | $3,557,000 |
| Normalized Income | $99,652,000 | $141,209,000 | $106,140,000 | $101,418,000 |
| Net Income From Continuing And Discontinued Operation | $99,652,000 | $141,209,000 | $106,140,000 | $101,418,000 |
| Total Operating Income As Reported | $44,797,000 | $136,951,000 | $107,282,000 | $112,634,000 |
| Net Income Common Stockholders | $98,171,000 | $139,733,000 | $105,496,000 | $101,288,000 |
| Net Income | $99,652,000 | $141,209,000 | $106,140,000 | $101,418,000 |
| Net Income Including Noncontrolling Interests | $99,652,000 | $141,209,000 | $106,140,000 | $101,418,000 |
| Net Income Continuous Operations | $99,652,000 | $141,209,000 | $106,140,000 | $101,418,000 |
| Pretax Income | $66,463,000 | $161,493,000 | $124,557,000 | $116,191,000 |
| Interest Income Non Operating | $21,666,000 | $24,542,000 | $17,275,000 | $3,557,000 |
| Operating Income | $44,797,000 | $136,951,000 | $107,282,000 | $112,634,000 |
| Gross Profit | $748,430,000 | $664,158,000 | $475,894,000 | $396,473,000 |
| Special Income Charges | - | $0 | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $0.82 | $1.23 | $0.94 | $0.87 |
| Basic EPS | $0.95 | $1.35 | $1.02 | $0.95 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $46,687,000 | $138,287,000 | $109,644,000 | $116,080,000 |
| Reconciled Depreciation | $1,890,000 | $1,336,000 | $2,362,000 | $3,446,000 |
| EBITDA (Bullshit earnings) | $46,687,000 | $138,287,000 | $109,644,000 | $116,080,000 |
| EBIT | $44,797,000 | $136,951,000 | $107,282,000 | $112,634,000 |
| Diluted Average Shares | $119,987,000 | $113,480,000 | $111,742,000 | $115,966,000 |
| Basic Average Shares | $103,862,000 | $103,232,000 | $103,560,000 | $106,787,000 |
| Diluted NI Availto Com Stockholders | $98,171,000 | $139,733,000 | $105,496,000 | $101,288,000 |
| Otherunder Preferred Stock Dividend | $1,481,000 | $1,476,000 | $644,000 | $130,000 |
| Tax Provision | $-33,189,000 | $20,284,000 | $18,417,000 | $14,773,000 |
| Research And Development | $254,908,000 | $246,887,000 | $184,353,000 | $130,991,000 |
| Selling General And Administration | $448,725,000 | $280,320,000 | $184,259,000 | $152,848,000 |
| Total Unusual Items | - | $0 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | - | $0 | $0 | $0 |
Fetched: 2026-07-10
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $647,805,000 | $679,589,000 | $506,705,000 | $501,842,000 |
| Total Assets | $836,651,000 | $840,553,000 | $621,517,000 | $583,430,000 |
| Total Non Current Assets | $351,187,000 | $368,951,000 | $162,881,000 | $84,177,000 |
| Other Non Current Assets | $16,247,000 | $10,193,000 | $14,785,000 | $15,989,000 |
| Non Current Deferred Assets | $168,197,000 | $130,914,000 | $90,605,000 | $61,465,000 |
| Non Current Deferred Taxes Assets | $168,197,000 | $130,914,000 | $90,605,000 | $61,465,000 |
| Investmentin Financial Assets | $160,270,000 | $219,831,000 | $57,176,000 | $4,947,000 |
| Current Assets | $485,464,000 | $471,602,000 | $458,636,000 | $499,253,000 |
| Other Current Assets | $7,102,000 | $6,078,000 | $5,882,000 | $16,424,000 |
| Current Deferred Assets | $5,061,000 | $4,493,000 | $13,496,000 | - |
| Prepaid Assets | $28,495,000 | $11,309,000 | $8,184,000 | - |
| Inventory | $12,868,000 | $12,412,000 | $7,730,000 | $6,100,000 |
| Receivables | $59,786,000 | $53,976,000 | $55,123,000 | $45,057,000 |
| Accounts Receivable | $59,786,000 | $53,976,000 | $41,123,000 | $31,057,000 |
| Cash Cash Equivalents And Short Term Investments | $372,152,000 | $383,334,000 | $368,221,000 | $431,672,000 |
| Cash And Cash Equivalents | $120,495,000 | $127,665,000 | $135,551,000 | $66,329,000 |
| Other Receivables | - | - | $14,000,000 | $14,000,000 |
| Debt | ||||
| Total Debt | $6,107,000 | $6,936,000 | $151,000 | $1,143,000 |
| Long Term Debt And Capital Lease Obligation | $5,023,000 | $6,107,000 | $0 | - |
| Current Debt And Capital Lease Obligation | $1,084,000 | $829,000 | $151,000 | $1,143,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $188,846,000 | $160,964,000 | $114,812,000 | $81,588,000 |
| Total Non Current Liabilities Net Minority Interest | $22,761,000 | $20,191,000 | $10,307,000 | $9,097,000 |
| Tradeand Other Payables Non Current | $15,176,000 | $14,084,000 | $10,307,000 | $9,097,000 |
| Current Liabilities | $166,085,000 | $140,773,000 | $104,505,000 | $72,491,000 |
| Other Current Liabilities | $6,914,000 | $4,044,000 | $654,000 | $763,000 |
| Current Deferred Liabilities | $35,679,000 | $41,580,000 | $18,468,000 | $11,098,000 |
| Payables And Accrued Expenses | $85,008,000 | $52,589,000 | $59,775,000 | $43,976,000 |
| Payables | $40,444,000 | $15,376,000 | $20,288,000 | $12,065,000 |
| Accounts Payable | $40,444,000 | $15,376,000 | $17,396,000 | $11,976,000 |
| Total Tax Payable | - | $191,000 | $2,892,000 | $89,000 |
| Income Tax Payable | - | $191,000 | $1,814,000 | $89,000 |
| Equity | ||||
| Common Stock Equity | $647,805,000 | $679,589,000 | $506,705,000 | $501,842,000 |
| Total Equity Gross Minority Interest | $647,805,000 | $679,589,000 | $506,705,000 | $501,842,000 |
| Stockholders Equity | $647,805,000 | $679,589,000 | $506,705,000 | $501,842,000 |
| Gains Losses Not Affecting Retained Earnings | $2,264,000 | $-217,000 | $609,000 | $-869,000 |
| Other Equity Adjustments | $2,264,000 | $-217,000 | $609,000 | $-869,000 |
| Retained Earnings | $643,387,000 | $543,735,000 | $402,526,000 | $296,386,000 |
| Other | ||||
| Treasury Shares Number | $36,552,000 | $32,640,000 | $30,939,000 | $23,124,000 |
| Ordinary Shares Number | $105,966,000 | $105,113,000 | $103,405,000 | $107,835,000 |
| Share Issued | $142,518,000 | $137,753,000 | $134,344,000 | $130,959,000 |
| Tangible Book Value | $647,805,000 | $679,589,000 | $506,705,000 | $501,842,000 |
| Invested Capital | $647,805,000 | $679,589,000 | $506,705,000 | $501,842,000 |
| Working Capital | $319,379,000 | $330,829,000 | $354,131,000 | $426,762,000 |
| Capital Lease Obligations | $6,107,000 | $6,936,000 | $151,000 | $1,143,000 |
| Total Capitalization | $647,805,000 | $679,589,000 | $506,705,000 | $501,842,000 |
| Treasury Stock | $966,586,000 | $696,173,000 | $635,078,000 | $456,148,000 |
| Additional Paid In Capital | $968,600,000 | $832,108,000 | $738,515,000 | $662,342,000 |
| Capital Stock | $140,000 | $136,000 | $133,000 | $131,000 |
| Common Stock | $140,000 | $136,000 | $133,000 | $131,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Accrued Expenses | $2,562,000 | $0 | - | - |
| Long Term Capital Lease Obligation | $5,023,000 | $6,107,000 | $0 | - |
| Current Deferred Revenue | $35,679,000 | $41,580,000 | $18,468,000 | $11,098,000 |
| Current Capital Lease Obligation | $1,084,000 | $829,000 | $151,000 | $1,143,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $37,400,000 | $41,731,000 | $25,457,000 | $15,511,000 |
| Current Accrued Expenses | $44,564,000 | $37,213,000 | $39,487,000 | $31,911,000 |
| Investments And Advances | $160,270,000 | $219,831,000 | $57,176,000 | $4,947,000 |
| Available For Sale Securities | $160,270,000 | $219,831,000 | $57,176,000 | $4,947,000 |
| Net PPE | $6,473,000 | $8,013,000 | $315,000 | $1,776,000 |
| Gross PPE | $6,473,000 | $8,013,000 | $315,000 | $1,776,000 |
| Other Properties | $6,473,000 | $8,013,000 | $315,000 | $1,776,000 |
| Inventories Adjustments Allowances | $-11,094,000 | $-3,583,000 | $-8,244,000 | $-10,931,000 |
| Finished Goods | $9,412,000 | $8,206,000 | $7,741,000 | $9,204,000 |
| Work In Process | $13,703,000 | $7,789,000 | $8,233,000 | $7,827,000 |
| Raw Materials | $847,000 | $0 | - | - |
| Other Short Term Investments | $251,657,000 | $255,669,000 | $232,670,000 | $365,343,000 |
| Accumulated Depreciation | - | - | - | $-3,707,000 |
| Leases | - | - | - | $1,597,000 |
| Machinery Furniture Equipment | - | - | - | $2,743,000 |
| Properties | - | - | - | $0 |
Fetched: 2026-07-10
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $141,785,000 | $196,123,000 | $126,542,000 | $119,910,000 |
| Operating Activities | ||||
| Operating Cash Flow | $141,996,000 | $198,295,000 | $126,681,000 | $120,323,000 |
| Cash Flow From Continuing Operating Activities | $141,996,000 | $198,295,000 | $126,681,000 | $120,323,000 |
| Investing Activities | ||||
| Capital Expenditure | $-211,000 | $-2,172,000 | $-139,000 | $-413,000 |
| Investing Cash Flow | $69,758,000 | $-177,604,000 | $90,906,000 | $-114,327,000 |
| Cash Flow From Continuing Investing Activities | $69,758,000 | $-177,604,000 | $90,906,000 | $-114,327,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $0 | $-145,428,000 | $0 |
| Financing Cash Flow | $-220,366,000 | $-28,349,000 | $-148,723,000 | $-17,284,000 |
| Cash Flow From Continuing Financing Activities | $-220,366,000 | $-28,349,000 | $-148,723,000 | $-17,284,000 |
| Net Other Financing Charges | $-72,941,000 | $-22,301,000 | $-9,106,000 | $-21,665,000 |
| Net Common Stock Issuance | $0 | $0 | $-145,428,000 | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $12,969,000 | $60,267,000 | $47,602,000 | $39,747,000 |
| End Cash Position | $120,495,000 | $127,665,000 | $135,551,000 | $66,329,000 |
| Beginning Cash Position | $127,665,000 | $135,551,000 | $66,329,000 | $77,617,000 |
| Effect Of Exchange Rate Changes | $1,442,000 | $-228,000 | $358,000 | - |
| Changes In Cash | $-8,612,000 | $-7,658,000 | $68,864,000 | $-11,288,000 |
| Proceeds From Stock Option Exercised | $-147,425,000 | $-6,048,000 | $5,811,000 | $4,381,000 |
| Common Stock Payments | $0 | $0 | $-145,428,000 | $0 |
| Net Investment Purchase And Sale | $69,969,000 | $-175,432,000 | $91,045,000 | $-113,914,000 |
| Sale Of Investment | $389,576,000 | $412,878,000 | $419,793,000 | $241,152,000 |
| Purchase Of Investment | $-319,607,000 | $-588,310,000 | $-328,748,000 | $-355,066,000 |
| Net PPE Purchase And Sale | $-211,000 | $-2,172,000 | $-139,000 | $-413,000 |
| Purchase Of PPE | $-211,000 | $-2,172,000 | $-139,000 | $-413,000 |
| Change In Working Capital | $-1,406,000 | $45,525,000 | $7,860,000 | $5,539,000 |
| Change In Other Current Liabilities | $-829,000 | $183,000 | $-1,289,000 | $-2,199,000 |
| Change In Other Current Assets | $1,457,000 | $-69,000 | $-1,483,000 | $-1,975,000 |
| Change In Payables And Accrued Expense | $30,174,000 | $38,537,000 | $31,036,000 | $32,503,000 |
| Change In Accrued Expense | $4,014,000 | $36,780,000 | $24,406,000 | $19,058,000 |
| Change In Payable | $26,160,000 | $1,757,000 | $6,630,000 | $13,445,000 |
| Change In Account Payable | $25,068,000 | $-2,020,000 | $5,420,000 | $4,757,000 |
| Change In Tax Payable | $1,092,000 | $3,777,000 | $1,210,000 | $8,688,000 |
| Change In Income Tax Payable | $1,092,000 | $3,777,000 | $1,210,000 | $8,688,000 |
| Change In Prepaid Assets | $-18,917,000 | $5,422,000 | $-11,603,000 | $-6,557,000 |
| Change In Inventory | $-7,481,000 | $305,000 | $1,265,000 | $1,199,000 |
| Change In Receivables | $-5,810,000 | $1,147,000 | $-10,066,000 | $-17,432,000 |
| Changes In Account Receivables | $-5,810,000 | $-12,853,000 | $-10,066,000 | $-3,432,000 |
| Stock Based Compensation | $84,500,000 | $61,354,000 | $48,940,000 | $42,442,000 |
| Amortization Of Securities | $-5,103,000 | $-10,938,000 | $-9,128,000 | $1,383,000 |
| Deferred Tax | $-37,537,000 | $-40,191,000 | $-29,493,000 | $-33,905,000 |
| Deferred Income Tax | $-37,537,000 | $-40,191,000 | $-29,493,000 | $-33,905,000 |
| Depreciation Amortization Depletion | $1,890,000 | $1,336,000 | $2,362,000 | $3,446,000 |
| Depreciation And Amortization | $1,890,000 | $1,336,000 | $2,362,000 | $3,446,000 |
| Depreciation | $1,890,000 | $1,336,000 | $2,362,000 | $3,446,000 |
| Net Income From Continuing Operations | $99,652,000 | $141,209,000 | $106,140,000 | $101,418,000 |
| Amortization Cash Flow | - | - | $465,000 | $477,000 |
| Amortization Of Intangibles | - | - | $465,000 | $477,000 |
| Other Non Cash Items | - | - | - | $1,383,000 |
Fetched: 2026-07-10